Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib

被引：58

作者：

Feng, Zhiqiang ^{[1
]}

Chu, Fengming ^{[1
]}

Guo, Zongru ^{[1
]}

Sun, Piaoyang ^{[2
]}

机构：

[1] Chinese Acad Med Sci, Inst Mat Med, Beijing 100050, Peoples R China

[2] Hengrui Pharmaceut Co, Lianyungang 222002, Jiangsu, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 08期

关键词：

Imrecoxib; Metabolites; Selective COX-2 inhibitor; CYCLOOXYGENASE-2; INHIBITOR; ROFECOXIB; SYNTHASE; RAT;

D O I：

10.1016/j.bmcl.2009.02.090

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We have developed a novel and moderately selective COX-2 inhibitor, imrecoxib, as a new anti-inflammatory drug. We describe herein the preparation of the major metabolites M2 and M4 of imrecoxib, as well as the in vitro and in vivo activities of the two compounds. The results showed that both M2 and M4 are potential COXs inhibitors with a moderate COX-1/COX-2 selectivity, and their anti-inflammatory activity in vivo was equal to or slightly higher than the clinical celecoxib. (c) 2009 Elsevier Ltd. All rights reserved.

引用

页码：2270 / 2272

页数：3

共 17 条

[1]

Bai AP, 2001, CHINESE CHEM LETT, V12, P775

[2] Recently reported inhibitors of cyclooxygenase-2 [J].

Carter, JS .

EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (01) :21-29

[3]

Chen XH, 2004, ACTA PHARMACOL SIN, V25, P927

[4] Adverse cardiovascular effects of the coxibs [J].

Dogné, JM ;

Supuran, CT ;

Pratico, D .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) :2251-2257

[5] DETECTION AND ISOLATION OF AN ENDOPEROXIDE INTERMEDIATE IN PROSTAGLANDIN BIOSYNTHESIS [J].

HAMBERG, M ;

SAMUELSS.B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1973, 70 (03) :899-903

[6] Prostaglandin synthase 2 [J].

Herschman, HR .

BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1996, 1299 (01) :125-140

[7]

MEADE EA, 1993, J BIOL CHEM, V268, P6610

[8] Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx™) [J].

Nicoll-Griffith, DA ;

Yergey, JA ;

Trimble, LA ;

Silva, JM ;

Li, C ;

Chauret, N ;

Gauthier, JY ;

Grimm, E ;

Léger, S ;

Roy, P ;

Thérien, M ;

Wang, ZY ;

Prasit, P ;

Zamboni, R ;

Young, RN ;

Brideau, C ;

Chan, CC ;

Mancini, J ;

Riendeau, D .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (23) :2683-2686

[9] The discovery of rofecoxib, [MK 966, Vioxx®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor [J].

Prasit, P ;

Wang, Z ;

Brideau, C ;

Chan, CC ;

Charleson, S ;

Cromlish, W ;

Ethier, D ;

Evans, JF ;

Ford-Hutchinson, AW ;

Gauthier, JY ;

Gordon, R ;

Guay, J ;

Gresser, M ;

Kargman, S ;

Kennedy, B ;

Leblanc, Y ;

Léger, S ;

Mancini, J ;

O'Neill, GP ;

Ouellet, M ;

Percival, MD ;

Perrier, H ;

Riendeau, D ;

Rodger, I ;

Tagari, P ;

Thérien, M ;

Vickers, P ;

Wong, E ;

Xu, LJ ;

Young, RN ;

Zamboni, R ;

Boyce, S ;

Rupniak, N ;

Forrest, N ;

Visco, D ;

Patrick, D .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (13) :1773-1778

[10]

ROGIER DJ, 1977, J MED CHEM, V40, P1347

← 1 2 →